Topal, GökçeDönmez, ArifUydeş-Doğan, B.SönmezKucur, MineCengiz, DicleBerkoz, Fatma BegümErdoğan, Nergis2020-11-212020-11-2120110009-9120https://doi.org/10.1016/j.clinbiochem.2011.01.011https://hdl.handle.net/11467/3498PubMed ID: 21291875Objective: The aim of the study was to investigate serum levels of asymmetric dimethylarginine (ADMA), tumor necrosis factor-? (TNF-?), interleukin-6 (IL-6) and plasma levels of 8-iso-prostaglandin F2? (8-iso-PGF2?) in patients with fibromyalgia. Design and method: Twenty-seven patients with fibromyalgia and twenty healthy controls were enrolled in this study. ADMA, TNF-?, IL-6 and 8-iso-PGF2? levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: Serum levels of ADMA and TNF-? and plasma levels 8-iso-PGF2? were significantly increased in patients with fibromyalgia compared to controls. However, no significant difference was observed in IL-6 levels between the two groups. ADMA concentrations were positively correlated with TNF-? and 8-iso-PGF2? levels in patients with fibromyalgia. Conclusion: This is the first study reporting that ADMA levels are significantly elevated in patients with fibromyalgia in association with increased 8-iso-PGF2? and TNF-? concentrations. Thereby, ADMA could be suggested as a reliable marker of endothelial dysfunction in patients with fibromyalgia. © 2011 The Canadian Society of Clinical Chemists.eninfo:eu-repo/semantics/closedAccess8-iso-PGF2?ADMAFibromyalgiaIL-6TNF-?Article4405.Jun364367Q2WOS:000288845000003Q22-s2.0-799527418822129187510.1016/j.clinbiochem.2011.01.011